Apellis Pharmaceuticals Inc. is a biopharmaceutical company that was founded in 2009 with the aim of developing innovative therapies to treat a range of serious medical conditions. The company's research and development efforts are centered around complement immunotherapy, a novel approach to addressing diseases involving the immune system.
Apellis' primary focus is on developing therapies that modulate the complement system, a part of the immune system involved in inflammation and immune responses. The company's lead product candidate is pegcetacoplan, which is being investigated for its potential to treat conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and geographic atrophy associated with age-related macular degeneration (AMD).
Apellis has been actively engaged in advancing its pipeline of product candidates beyond pegcetacoplan, with a focus on addressing various complement-mediated diseases and disorders. The company's innovative approach to modulating the immune system's complement system positions it as a significant player in the field of immunotherapy.